Increased peritoneal TGF-β1 is associated with ascites-induced NK-cell dysfunction and reduced survival in high-grade epithelial ovarian cancer

Front Immunol. 2024 Sep 23:15:1448041. doi: 10.3389/fimmu.2024.1448041. eCollection 2024.

Abstract

Natural killer (NK) cell therapy represents an attractive immunotherapy approach against recurrent epithelial ovarian cancer (EOC), as EOC is sensitive to NK cell-mediated cytotoxicity. However, NK cell antitumor activity is dampened by suppressive factors in EOC patient ascites. Here, we integrated functional assays, soluble factor analysis, high-dimensional flow cytometry cellular component data and clinical parameters of advanced EOC patients to study the mechanisms of ascites-induced inhibition of NK cells. Using a suppression assay, we found that ascites from EOC patients strongly inhibits peripheral blood-derived NK cells and CD34+ progenitor-derived NK cells, albeit the latter were more resistant. Interestingly, we found that higher ascites-induced NK cell inhibition correlated with reduced progression-free and overall survival in EOC patients. Furthermore, we identified transforming growth factor (TGF)-β1 to correlate with ascites-induced NK cell dysfunction and reduced patient survival. In functional assays, we showed that proliferation and anti-tumor reactivity of CD34+ progenitor-derived NK cells are significantly affected by TGF-β1 exposure. Moreover, inhibition of TGF-β1 signaling with galunisertib partly restored NK cell functionality in some donors. For the cellular components, we showed that the secretome is associated with a different composition of CD45+ cells between ascites of EOC and benign reference samples with higher proportions of macrophages in the EOC patient samples. Furthermore, we revealed that higher TGF-β1 levels are associated with the presence of M2-like macrophages, B cell populations and T-regulatory cells in EOC patient ascites. These findings reveal that targeting TGF-β1 signaling could increase NK cell immune responses in high-grade EOC patients.

Keywords: TGF-β; ascites; natural killer (NK) cells; ovarian cancer; tumor microenvironment.

MeSH terms

  • Aged
  • Ascites* / immunology
  • Carcinoma, Ovarian Epithelial* / immunology
  • Carcinoma, Ovarian Epithelial* / mortality
  • Female
  • Humans
  • Killer Cells, Natural* / immunology
  • Killer Cells, Natural* / metabolism
  • Middle Aged
  • Neoplasm Grading
  • Ovarian Neoplasms* / immunology
  • Ovarian Neoplasms* / mortality
  • Ovarian Neoplasms* / pathology
  • Pyrazoles / pharmacology
  • Pyrazoles / therapeutic use
  • Quinolines
  • Transforming Growth Factor beta1* / metabolism

Substances

  • Transforming Growth Factor beta1
  • TGFB1 protein, human
  • LY-2157299
  • Pyrazoles
  • Quinolines

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by a grant from RIMLS 2016-7. DT is supported by a Hypatia Fellowship grant from the Radboudumc.